A platform that goals to vary outcomes for canine recognized with most cancers not too long ago acquired $10 million in new funding that may permit the corporate to develop and provides extra canine entry to precision therapy.
FidoCure makes use of genetic testing to determine what genetic mutation may be behind a canine’s most cancers. As soon as testing is full, FidoCure gives precision drugs reviews with suggestions for individualized, focused remedy utilizing the newest science out there in each human and canine oncology. FidoCure is out there nationwide by means of greater than 200 taking part veterinarians.
To study extra, go to fidocure.com.